Novartis

The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Yahoo/Benzinga
JNJ
Flexion Therapeutics
Novartis
Amgen
Clearside Biomedical
Alexion
Assertio Therapeutics
Aldeyra Therapeutics
Lineage Therapeutics
IMMUTEP
Marinus Pharma
Flag link:
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
BioSpace
Genentech
Pfizer
Merck
Amgen
Novartis
Flag link:
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Pharmafile
Novartis
clinical trials
ligelizumab
Roche
Xolair
chronic urticaria
Flag link:
Eylea casts a shadow over Novartis' latest approval
Eylea casts a shadow over Novartis' latest approval
Biopharma Dive
Novartis
Beovu
wet age-related macular degeneration
Regeneron
Eylea
Flag link:
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Flag link:
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Pharmaforum
Novartis
brolucizumab
Bayer
Eylea
wet age-related macular degeneration
FDA
Flag link:
Recent Job Cuts in the Biopharma Industry
Recent Job Cuts in the Biopharma Industry
BioSpace
Tocagen
Sanofi
Amneal
Daiichi Sankyo
Integra Life Sciences
Aclaris
Bayer
Novartis
Illumina
Merck
Roche Molecular Systems
Prometheus Labs
layoffs
Flag link:
Novartis' latest Zolgensma data bode well for use in older patients
Novartis' latest Zolgensma data bode well for use in older patients
Fierce Pharma
Novartis
Zolgensma
SMA
FDA
spinal muscular atrophy
Flag link:
It May Be Time For Standard Breast Cancer Treatment To Change
It May Be Time For Standard Breast Cancer Treatment To Change
Forbes
breast cancer
HER2-negative breast cancer
Novartis
ribociclib
Flag link:
A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering
A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering
Investors Business Daily
Coherus Biosciences
Novartis
Udenyca
Neulasta
biosmilars
Flag link:
Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis
Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis
Endpoints
Novartis
Cosentyx
axial spondyloarthritis
Flag link:
Why Bausch Health Companies Stock Sank Today
Why Bausch Health Companies Stock Sank Today
Motley Fool
Bausch Health
Novartis
Sandoz
Xifaxan
patents
Flag link:
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Globe Newswire
Novartis
Microsoft
artificial intelligence
innovation
drug development
Flag link:
ESMO: Eyeing Novartis and Pfizer, Chi-Med touts neuroendocrine cancer win
ESMO: Eyeing Novartis and Pfizer, Chi-Med touts neuroendocrine cancer win
Fierce Pharma
Chi-Med
surufatinib
Pfizer
Sutent
Novartis
Afinitor
Lutathera
neuroendocrine tumors. ESMO
Flag link:
Novartis announces positive results from asthma combinations
Novartis announces positive results from asthma combinations
Pharmaforum
Novartis
asthma
QMF149
QVM149
clinical trials
Flag link:
Blow to Novartis as NICE rejects migraine drug Aimovig again
Blow to Novartis as NICE rejects migraine drug Aimovig again
Pharmaforum
Novartis
Aimovig
migraines
NICE
Flag link:
GlaxoSmithKline halts generic Zantac supply as global threat gains steam
GlaxoSmithKline halts generic Zantac supply as global threat gains steam
Fierce Pharma
Novartis
GSK
generics
OTC
Zantac
product recalls
Flag link:
Novartis to put AveXis into protective custody after data manipulation scandal
Novartis to put AveXis into protective custody after data manipulation scandal
Fierce Pharma
Novartis
AveXis
Zolgensma
Flag link:
Novartis in political row after denying Belgian toddler compassionate access to gene therapy
Novartis in political row after denying Belgian toddler compassionate access to gene therapy
Pharmaforum
Novartis
Zolgensma
SMA
compassionate use guidelines
Flag link:
Novartis, shadowed by data scandal, renews case for Zolgensma
Novartis, shadowed by data scandal, renews case for Zolgensma
Biopharma Dive
Novartis
Zolgensma
SMA
spinal muscular atrophy
Flag link:

Pages